Precision medicine-guided synthetic lethality targeting DNA repair to eradicate

Precision medicine-guided synthetic lethality targeting DNA repair to eradicate solid tumors

2016/22/M/NZ7/00375

Keywords

Descriptors

NZ7_14: Farmacja, farmakoterapia, farmakologia

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Voivodeship: łódzkie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr hab. Tomasz Śliwiński

Number of co-investigators in the project: 10

Call

HARMONIA 8 – announced on 2016-06-15

Amount awarded: 923 000 PLN
Project start date: 2017-04-13
Project end date: 2022-02-12
Project duration: 58 months (the same as in the proposal)
Project status: Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (6)

Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells

Authors:
Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T.

Academic press:
Journal of Personalized Medicine (year: 2023, volume: 13, pages: 1315), Publisher: MDPI

Status:
Published

DOI:
10.3390/jpm13091315 – link to the publication
DNA double strand break repair - related synthetic lethality.

Authors:
Toma M, Skorski T, Sliwinski T.

Academic press:
Curr Med Chem (year: 2018, volume: 25, pages: 13516), Publisher: Bentham Science

Status:
Published

DOI:
10.2174/0929867325666180201114306 – link to the publication
Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor

Authors:
Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jaśniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyż M, Skorski T, Śliwiński T

Academic press:
Genes (year: 2023, volume: 14(6), pages: 1295-1307), Publisher: MDPI

Status:
Published

DOI:
10.3390/genes14061295 – link to the publication
Eradication of LIG4-defficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent

Authors:
Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska-Skorska M, Radek M, Kolasa P, Matlawska-WasowskaK Sliwinski T, Skorski T

Academic press:
Oncotarget (year: 2018, volume: 9, pages: 36867-36877), Publisher: Impact Journals

Status:
Published

DOI:
10.18632/oncotarget.26409 – link to the publication
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies

Authors:
Toma M, Sullivan-Reed K, Śliwiński T, Skorski T

Academic press:
Cancers (year: 2019, volume: 11, pages: 1561), Publisher: MDPI

Status:
Published

DOI:
10.3390/cancers11101561 – link to the publication
Synthetic lethality targeting Polθ

Authors:
Małgorzata Drzewiecka, Gabriela Barszczewska-Pietraszek, Piotr Czarny, Tomasz Skorski, Tomasz Śliwiński

Academic press:
Genes (year: 2022, volume: 13, pages: 1101), Publisher: MDPI

Status:
Published

DOI:
10.3390/genes13061101 – link to the publication

« New search

Projects search